LeMaitre Vascular is rated a "Strong Buy" due to its robust M&A-driven business model, high margins, and recent valuation compression. LMAT's strategic shift to larger, higher-multiple acquisitions has improved its success rate to 80% and driven margin expansion, with gross margin rising from 65% to 72%. The company's healthy balance sheet, $376M in cash/short-term investments, and experienced management underpin its ability to pursue disciplined, accretive deals.
LeMaitre Vascular remains a Buy after a 31% pullback, though I have trimmed my price target to $95-$100 for year-end 2027. The Q2 2026 miss was tied to currency, export blockages, and tissue shortages. Not underlying demand. Organic sales grew 10%, and margins hit record highs. Artegraft, now 21% of sales, is LMAT's largest and fastest-growing product. It is the main factor behind margin expansion and international growth prospects.
LeMaitre Vascular, Inc. (LMAT) Q2 2026 Earnings Call Transcript
| Electronic Equipment, Instruments & Components Industry | Information Technology Sector | George W. LeMaitre CEO | XSTU Exchange | 525558201 CUSIP |
| US Country | 651 Employees | 20 Aug 2026 Last Dividend | - Last Split | 19 Oct 2006 IPO Date |
LeMaitre Vascular, Inc. is a global company focused on the design, manufacture, and marketing of medical devices and implants for vascular surgery. Initially founded as Vascutech, Inc., the company transitioned to its current name in April 2001. With its beginnings in 1983 and headquartered in Burlington, Massachusetts, LeMaitre Vascular stands as a pioneer in the vascular health sector. It offers a diverse range of products, including devices for blood vessel viewing, blood clot removal, and vascular reconstruction, catering to the needs of surgeons and patients worldwide. The company’s approach combines innovative technology with practical applications in vascular surgery, distributing its products through a direct sales force and a network of distributors.